
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
This report includes a study on patterns of prodromal psychiatric symptoms that may help identify young persons at increased risk of bipolar disorder; sibling bullying and risk of psychotic disorders; and a new smartphone app that tracks moods and predicts bipolar disorder episodes.